[go: up one dir, main page]

MX2021013743A - Subunidad s1 modificada de la proteina de espicula de coronavirus. - Google Patents

Subunidad s1 modificada de la proteina de espicula de coronavirus.

Info

Publication number
MX2021013743A
MX2021013743A MX2021013743A MX2021013743A MX2021013743A MX 2021013743 A MX2021013743 A MX 2021013743A MX 2021013743 A MX2021013743 A MX 2021013743A MX 2021013743 A MX2021013743 A MX 2021013743A MX 2021013743 A MX2021013743 A MX 2021013743A
Authority
MX
Mexico
Prior art keywords
coronavirus
protein
spicle
subunit
modified
Prior art date
Application number
MX2021013743A
Other languages
English (en)
Inventor
Annika Kraemer-Kuehl
Hans-Christian Philipp
Thomas Min Stephan
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2021013743A publication Critical patent/MX2021013743A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere, entre otras cosas, a una proteína de espícula de coronavirus aviar recombinante o fragmento de la misma que comprende una mutación en la posición de aminoácido 267 en cisteína. Además, la presente invención se refiere a una composición inmunogénica que comprende un coronavirus aviar con dicha proteína de espícula.
MX2021013743A 2019-05-10 2020-05-06 Subunidad s1 modificada de la proteina de espicula de coronavirus. MX2021013743A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19173821 2019-05-10
EP19212627 2019-11-29
PCT/EP2020/062526 WO2020229248A1 (en) 2019-05-10 2020-05-06 Modified s1 subunit of the coronavirus spike protein

Publications (1)

Publication Number Publication Date
MX2021013743A true MX2021013743A (es) 2021-12-10

Family

ID=70471064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013743A MX2021013743A (es) 2019-05-10 2020-05-06 Subunidad s1 modificada de la proteina de espicula de coronavirus.

Country Status (9)

Country Link
US (2) US11512115B2 (es)
EP (1) EP3965812A1 (es)
JP (2) JP2022531731A (es)
KR (1) KR20220007155A (es)
CN (1) CN114126645B (es)
CO (1) CO2021014778A2 (es)
IL (1) IL287763A (es)
MX (1) MX2021013743A (es)
WO (1) WO2020229248A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112941091A (zh) * 2021-03-17 2021-06-11 吉林大学 一种猪血凝性脑脊髓炎dna疫苗及其制备方法
GB202107057D0 (en) 2021-05-18 2021-06-30 Univ York Glycosylation method
CN114262694B (zh) * 2021-12-06 2023-11-03 军事科学院军事医学研究院军事兽医研究所 以B型流感病毒为载体的SARS-CoV-2疫苗候选株及其构建方法和应用
CN114276423B (zh) * 2021-12-21 2023-04-07 易康生物(苏州)有限公司 猪传染性胃肠炎病毒的s蛋白突变体及其应用
KR102597501B1 (ko) 2022-12-19 2023-11-03 주식회사 티지네트워크 Rf필터 검사 및 학습 시스템과 그 방법
KR102717877B1 (ko) * 2023-06-16 2024-10-16 주식회사 지나이너 외래 qx 유사 바이러스 스파이크 단백질을 포함하는 전염성 기관지염 키메라 바이러스 및 이를 포함하는 백신 조성물
US20250064920A1 (en) 2023-08-03 2025-02-27 Boehringer Ingelheim Vetmedica Gmbh Ibv vaccine with heterologous dmv/1639 spike protein

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5032520A (en) 1985-03-29 1991-07-16 National Research Development Corporation DNA sequences encoding infectious bronchitis virus spike protein
WO2001009290A2 (es) 1999-07-30 2001-02-08 Laboratorio Avi-Mex, S.A. De C.V. Serotipo de virus de bronquitis infecciosa aviar
ATE463253T1 (de) 2000-02-29 2010-04-15 Wyeth Llc In ovo schutz gegen infektiöse bronchitis
CA2522379C (en) 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
US8679504B2 (en) 2008-05-22 2014-03-25 University Of Georgia Research Foundation Inc. Poultry viral materials and methods related thereto
GB0911794D0 (en) 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein
US20140141043A1 (en) 2012-11-16 2014-05-22 Auburn University Compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus
GB201308057D0 (en) * 2013-05-03 2013-06-12 Pirbright Inst The Protein
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
US9790474B2 (en) 2014-07-24 2017-10-17 University Of Georgia Research Foundation, Inc. Attenuation of infectious bronchitis virus variant GA-13
US9764025B2 (en) 2014-10-20 2017-09-19 Auburn University Adaptation of attenuated infectious bronchitis virus (IBV) to embryonic kidney cells and vaccine thereby produced
MX2018015506A (es) 2016-06-16 2019-05-22 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra virus de bronquitis infecciosa.
WO2018140714A1 (en) 2017-01-27 2018-08-02 University Of Georgia Research Foundation, Inc. Live attenuated arkansas serotype infectious bronchitis virus vaccine
US10772953B2 (en) * 2017-08-09 2020-09-15 Auburn University Recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus
WO2019046634A1 (en) 2017-08-30 2019-03-07 Peption, LLC METHOD FOR GENERATING INTERACTIVE PEPTIDES
CN112996537B (zh) 2018-10-31 2025-04-25 勃林格殷格翰动物保健有限公司 具有异源刺突蛋白的4/91 ibv疫苗
MY206043A (en) 2018-10-31 2024-11-26 Boehringer Ingelheim Vetmedica Gmbh H52 ibv vaccine with heterologous spike protein

Also Published As

Publication number Publication date
CN114126645B (zh) 2025-04-25
JP2022531731A (ja) 2022-07-08
US20230340028A1 (en) 2023-10-26
KR20220007155A (ko) 2022-01-18
CO2021014778A2 (es) 2021-11-19
BR112021022651A2 (pt) 2021-12-28
CN114126645A (zh) 2022-03-01
US11999766B2 (en) 2024-06-04
EP3965812A1 (en) 2022-03-16
IL287763A (en) 2022-01-01
WO2020229248A1 (en) 2020-11-19
US11512115B2 (en) 2022-11-29
JP2024028744A (ja) 2024-03-05
US20200354410A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
ATE549028T1 (de) Stabile analoga von glp-1
EA201890220A1 (ru) Вакцина против rsv
CY1118676T1 (el) Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c)
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
EA201991065A1 (ru) Вакцина против свиного парвовируса
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MX2022007881A (es) Proteina f mutante del virus sincitial respiratorio (rsv) y usos de la misma.
EA200701528A1 (ru) Новые нутрицевтические композиции
SA518400460B1 (ar) مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
EA202190999A1 (ru) Композиции на основе полипептидов, стабилизированных с помощью дисульфидной связи, и способы применения
PH12019550241A1 (en) Mic-1 compounds and uses thereof
CL2020002597A1 (es) Métodos para preparar composiciones proteicas estables
EA201100071A1 (ru) Новые композиции и способы
JO2963B1 (en) Reconstructed surfactants with improved properties
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
AR116876A1 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
JOP20220093A1 (ar) تركيبة صيدلانية تشتمل على سيليكسيباغ
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
CR20220206A (es) Agonistas del receptor npy2